Yasho Industries posted a robust 313% year-on-year increase in profit after tax to ₹25.26 crore for FY26. The company also announced a significant 15-year supply agreement with a global MNC, expected to add ₹150 crore in annual revenue.
Yasho Industries Posts Strong FY26 Results, Secures Landmark MNC Deal
Profit After Tax (PAT) surged 313.4% to ₹25.26 crore; Revenue from operations grew 22.85% to ₹830.03 crore.
Reader Takeaway: Strong profit growth and a long-term supply deal offer revenue visibility, but geopolitical risks loom.
What just happened
Yasho Industries Ltd. has reported impressive financial results for the fiscal year 2025-26. The company's consolidated revenue from operations reached ₹830.03 crore, marking a significant 22.85% increase compared to the previous fiscal year. Profit After Tax (PAT) saw a substantial surge of 313.4%, climbing to ₹25.26 crore from ₹6.11 crore in FY 2024-25. This growth was driven by a 33% volume increase and an optimized product mix, with the industrial chemicals segment contributing 87% of the revenue.
Why this matters
This performance is crucial for investors as it signals robust operational efficiency and strategic execution. The sharp rise in profitability, coupled with improved operating and net profit margins, indicates effective cost management and better pricing power. The most significant development is the 15-year supply agreement with a global multinational corporation (MNC) for lubricant additives. This deal is projected to generate approximately ₹150 crore in annual revenue starting from Q1 FY 2027-28, providing substantial long-term revenue visibility and de-risking future growth.
The backstory
Yasho Industries is a manufacturer of specialty chemicals. The company has been focusing on expanding its capacities and product portfolio. In FY 2025-26, it invested ₹75.20 crore in capital expenditure, including the installation of two new manufacturing lines at its Pakhajan facility. Additionally, a new R&D laboratory was commissioned at Pakhajan with an investment of ₹25.30 crore to foster product innovation and expand its specialty chemicals offerings.
What changes now
The long-term supply agreement provides a clear revenue stream for the next 15 years, which is a significant de-risking event. The new manufacturing lines are expected to cater to high-growth product categories, supporting this expanded demand. The company has set a clear target of achieving ₹1,500 crore in revenue by FY 2027-28, a goal that this new contract will substantially help achieve.
Risks to watch
While the financial performance is strong, potential risks remain. The company highlighted geopolitical and market risks, including trade restrictions and pricing pressures, which could impact performance, particularly in export markets. Additionally, a watch point noted is the company's CSR compliance; it failed to spend 2% of its average net profit during FY 25-26 due to pending approvals.
Peer comparison
(Information not available in the provided text. No direct peer comparison can be made.)
Context metrics (time-bound)
- Consolidated Revenue for FY 2025-26: ₹ 830.03 crore (up 22.85% YoY)
- Consolidated Profit After Tax (PAT) for FY 2025-26: ₹ 25.26 crore (up 313.4% YoY)
- Operating Profit Margin for FY 2025-26: 24.84% (up 3.14 bps YoY)
- Net Profit Margin for FY 2025-26: 3.04% (up 2.14 bps YoY)
- Capex in FY 2025-26: ₹ 75.20 crore
- R&D Investment: ₹ 25.30 crore (for new lab)
- Projected Annual Revenue from MNC Deal: ₹ 150 crore (starting Q1 FY 2027-28)
What to track next
Investors will be keen to monitor the successful integration of the new manufacturing lines and the ramp-up of production for the MNC supply agreement. Closely watching the company's ability to navigate geopolitical tensions and pricing pressures will be crucial. Additionally, tracking CSR compliance in future periods will be important for governance-conscious investors.